Clinical trials assessing the efficacy of BCMA-targeted therapies in earlier lines of therapy
| Trial . | No. of prior lines of therapy . | Median PFS, mo (median follow up) . | ORR, n (%); CR, n(%); MRD, n(%) . | Hazard ratio (95% CI) . |
|---|---|---|---|---|
| Cilta-cel trials | ||||
| CARTITUDE-239 | 1-3 | N/A | 18 (88.9); 18 (27.8); 9 (100) | N/A |
| CARTITUDE-437 | 1-3 | Not reached (15.9 mo) | 176 (85); 152 (73); 126 (61) | 0.26 (0.18-0.38) (P < .0001) |
| CARTITUDE-540 | 0 (NDMM, TI) | N/A (recruiting) | N/A | N/A |
| CARTITUDE-6 [NCT05257083] | 0 (NDMM, TE) | N/A (recruiting) | N/A | N/A |
| Ide-cel trials | ||||
| KarMMa-241 | 1-3 | N/A (recruiting) | 37 (83.8); 37 (45.9); 13 (85) | N/A |
| KarMMa-338 | 2-4 | 13.3 (18.6) | 181 (71); 98 (39); 50 (20) | 0.49 (0.38-0.65) (P < .001) |
| KarMMa-442 | 0 (NDMM, high-risk) | N/A | N/A | N/A |
| KarMMa-743 | 1-3 | N/A | N/A | N/A |
| Elranatamab trials | ||||
| MagnetisMM-144 | 2-15 | 55 (64); 35 (31); N/A | ||
| MagnetisMM-345 | 123 (61); 123 (35); 29 (89.7) | |||
| MagnetisMM- 446 | ≥3 | N/A | N/A | N/A |
| MagnetisMM-547 | >1 | N/A | N/A | N/A |
| Teclistamab trial | ||||
| MajesTEC-348 | 1-3 | N/A (recruiting) | N/A | N/A |
| Talquetamab trials | ||||
| TRIMM-249 | >3 | N/A | 50 (78); 50 (16); N/A | N/A |
| RedirecTT-150 | On/after lines of therapy | 20.9 (13.4) | 93 (86.6); 93 (22); N/A | N/A |
| Trial . | No. of prior lines of therapy . | Median PFS, mo (median follow up) . | ORR, n (%); CR, n(%); MRD, n(%) . | Hazard ratio (95% CI) . |
|---|---|---|---|---|
| Cilta-cel trials | ||||
| CARTITUDE-239 | 1-3 | N/A | 18 (88.9); 18 (27.8); 9 (100) | N/A |
| CARTITUDE-437 | 1-3 | Not reached (15.9 mo) | 176 (85); 152 (73); 126 (61) | 0.26 (0.18-0.38) (P < .0001) |
| CARTITUDE-540 | 0 (NDMM, TI) | N/A (recruiting) | N/A | N/A |
| CARTITUDE-6 [NCT05257083] | 0 (NDMM, TE) | N/A (recruiting) | N/A | N/A |
| Ide-cel trials | ||||
| KarMMa-241 | 1-3 | N/A (recruiting) | 37 (83.8); 37 (45.9); 13 (85) | N/A |
| KarMMa-338 | 2-4 | 13.3 (18.6) | 181 (71); 98 (39); 50 (20) | 0.49 (0.38-0.65) (P < .001) |
| KarMMa-442 | 0 (NDMM, high-risk) | N/A | N/A | N/A |
| KarMMa-743 | 1-3 | N/A | N/A | N/A |
| Elranatamab trials | ||||
| MagnetisMM-144 | 2-15 | 55 (64); 35 (31); N/A | ||
| MagnetisMM-345 | 123 (61); 123 (35); 29 (89.7) | |||
| MagnetisMM- 446 | ≥3 | N/A | N/A | N/A |
| MagnetisMM-547 | >1 | N/A | N/A | N/A |
| Teclistamab trial | ||||
| MajesTEC-348 | 1-3 | N/A (recruiting) | N/A | N/A |
| Talquetamab trials | ||||
| TRIMM-249 | >3 | N/A | 50 (78); 50 (16); N/A | N/A |
| RedirecTT-150 | On/after lines of therapy | 20.9 (13.4) | 93 (86.6); 93 (22); N/A | N/A |
N/A, not applicable.